|1.||Nicoletti, Ferdinando: 8 articles (06/2013 - 05/2009)|
|2.||Al-Abed, Yousef: 7 articles (10/2012 - 05/2009)|
|3.||Mangano, Katia: 6 articles (06/2013 - 05/2009)|
|4.||Stosic-Grujicic, Stanislava: 6 articles (10/2012 - 05/2009)|
|5.||Maksimovic-Ivanic, Danijela: 6 articles (10/2012 - 05/2009)|
|6.||Mijatovic, Sanja: 6 articles (10/2012 - 05/2009)|
|7.||Fagone, Paolo: 5 articles (06/2013 - 02/2011)|
|8.||Mojic, Marija: 5 articles (10/2012 - 05/2009)|
|9.||Miljkovic, Djordje: 5 articles (10/2012 - 05/2009)|
|10.||Zocca, Mai-Britt: 4 articles (06/2013 - 03/2012)|
|1.||HIV Infections (HIV Infection)
03/01/1998 - "Initial results of trials evaluating the therapeutic efficacy of saquinavir SGC-containing combination therapy in patients with moderate to advanced HIV infection are promising. "
12/08/1995 - "[The safety and efficacy of saquinavir in the therapy of HIV infection]."
01/01/2013 - "The goal of this study was to develop and characterize an intravaginal nanomedicine for the active targeted delivery of saquinavir (SQV) to CD4(+) immune cells as a potential strategy to prevent or reduce HIV infection. "
08/01/2000 - "Data (up to 48 weeks) from noncomparative and comparative clinical trials evaluating saquinavir SGC-containing combination regimens in adult patients with HIV infection, support and strengthen the clinical efficacy profile of the drug that was demonstrated in initial trials. "
01/01/2003 - "Saquinavir: a review of its use in boosted regimens for treating HIV infection."
12/01/1991 - "These properties indicate that Ro 31-8959 is highly effective against HIV with the potential to inhibit acute, established acute and chronic infections."
11/01/1992 - "Phase I/II clinical trials of Ro 31-8959 for therapy of HIV-1 infection are in progress. "
04/01/2005 - "The presence of HIV-1 PR inhibitor saquinavir from 24h post-infection prevented virus-induced cell lysis. "
01/28/2005 - "Short-course induction with boosted saquinavir monotherapy for naive patients with late-stage infection."
03/01/2002 - "Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection."
|3.||Acquired Immunodeficiency Syndrome (AIDS)
11/01/2005 - "AIDS Clinical Trials Group (ACTG) 359 was a randomized, partially double-blinded factorial study of 6 antiretroviral regimens, all including saquinavir, among HIV-infected persons in whom prior therapy had failed (n = 258). "
04/01/2004 - "Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359."
05/01/2002 - "A randomized, open-label, comparative trial of BID and TID dosing of saquinavir enhanced oral formulation as part of a triple therapy for advanced AIDS patients."
11/01/1994 - "Saquinavir mesylate (Hoffmann-La Roche, Nutley, NJ) is the most extensively tested and appears to have activity, as assessed by immunologic and virologic methods in small trials and in one AIDS Clinical Trials Group study. "
11/01/2007 - "Saquinavir (SQV) was the first HIV-1 PR inhibitor licensed for clinical use and widely used for acquired immunodeficiency syndrome (AIDS) therapy. "
04/01/2013 - "Higher saquinavir exposure was predicted in patients relative to healthy subjects, which was explained by the altered drug binding due to elevated AAG levels in patients with cancer. "
12/01/2010 - "Saq-NO exerted anticancer effects in lower concentrations than saquinavir in a panel of human cancer cell lines. "
03/01/2009 - "Given the challenges of chemoresistance in ovarian cancer, saquinavir may have particular benefit in the treatment of chemoresistant tumors that may respond to the induction of caspase-independent cell death by mechanisms such as autophagy."
01/01/2011 - "Accordingly, therapeutic steadystate concentrations of indinavir or saquinavir were highly effective in inhibiting invasion of tumor cells in vitro. "
12/01/2010 - "Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells."
04/01/1998 - "In logistic regression analysis, saquinavir use was the only factor associated with a significantly greater risk of severe mucositis (relative risk 7.9; P = 0.03). "
04/01/1998 - "Severe (grade 3 or 4) mucositis occurred in eight of 12 patients (67%) treated with CDE plus saquinavir compared with three of 25 patients (12%) in our prior study treated with CDE without saquinavir (P < 0.001). "
04/01/1998 - "Combination of the protease inhibitor saquinavir with infusional CDE in patients with HIV-associated lymphoma was associated with a significant increase in the incidence of severe mucositis. "
|4.||Protease Inhibitors (Protease Inhibitor)
|5.||Reverse Transcriptase Inhibitors
|6.||Biological Markers (Surrogate Marker)
|9.||RNA (Ribonucleic Acid)
|2.||First Aid (Aids, First)
|3.||Contraception (Birth Control)
|4.||Drug Therapy (Chemotherapy)
|5.||Highly Active Antiretroviral Therapy (HAART)